Research Focus

Clinical Pipeline

Melanocortin Receptor Programs Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Submission FDA Approval

Vyleesi® (bremelanotide) MC4r Agonist

Hypoactive Sexual Desire Disorder

PL9643 MCr Agonist

Dry Eye Disease

PL8177 MC1r Agonist (Systemic)

Non-Infectious Uveitis

PL8331 MCr Agonist

Diabetic Retinopathy

PL8177 MC1r Agonist (Oral)

Inflammatory Bowel Diseases

MC4r Agonist Peptide & Small Molecules

Rare Genetic Metabolic and Obesity Disorders

Natriuretic Peptide Receptor Programs Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Submission FDA Approval

PL3994 NPR-A

Cardiovascular Disease

PL5028 NPR-A/C Agonist

Cardiovascular and Fibrotic Diseases